149 related articles for article (PubMed ID: 38011601)
1. Killing a fly with a sledgehammer: Atezolizumab exposure in real-world lung cancer patients.
Marolleau S; Mogenet A; Boeri C; Hamimed M; Ciccolini J; Greillier L
CPT Pharmacometrics Syst Pharmacol; 2023 Nov; 12(11):1795-1803. PubMed ID: 38011601
[TBL] [Abstract][Full Text] [Related]
2. In Silico Re-Optimization of Atezolizumab Dosing Using Population Pharmacokinetic Simulation and Exposure-Response Simulation.
Peer CJ; Schmidt KT; Arisa O; Richardson WJ; Paydary K; Goldstein DA; Gulley JL; Figg WD; Ratain MJ
J Clin Pharmacol; 2023 Jun; 63(6):672-680. PubMed ID: 36624662
[TBL] [Abstract][Full Text] [Related]
3. Model-based simulation to support the extended dosing regimens of atezolizumab.
Chou CH; Hsu LF
Eur J Clin Pharmacol; 2021 Jan; 77(1):87-93. PubMed ID: 32808071
[TBL] [Abstract][Full Text] [Related]
4. Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting.
Morrissey KM; Marchand M; Patel H; Zhang R; Wu B; Phyllis Chan H; Mecke A; Girish S; Jin JY; Winter HR; Bruno R
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1257-1267. PubMed ID: 31542806
[TBL] [Abstract][Full Text] [Related]
5. [Standard technical specifications for methacholine chloride (Methacholine) bronchial challenge test (2023)].
; ;
Zhonghua Jie He He Hu Xi Za Zhi; 2024 Feb; 47(2):101-119. PubMed ID: 38309959
[TBL] [Abstract][Full Text] [Related]
6. Results of a Dose-Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
Felip E; Burotto M; Zvirbule Z; Herraez-Baranda LA; Chanu P; Kshirsagar S; Maiya V; Chan P; Pozzi E; Marchand M; Monchalin M; Tanaka K; Tosti N; Wang B; Restuccia E
Clin Pharmacol Drug Dev; 2021 Oct; 10(10):1142-1155. PubMed ID: 33788415
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer.
Shemesh CS; Chanu P; Jamsen K; Wada R; Rossato G; Donaldson F; Garg A; Winter H; Ruppel J; Wang X; Bruno R; Jin J; Girish S
J Immunother Cancer; 2019 Nov; 7(1):314. PubMed ID: 31753029
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics (PK) of Tiragolumab in First-in-Human Study in Patients with Mixed Solid Tumors (GO30103).
Garralda E; Oh DY; Italiano A; Bedard PL; Delord JP; Calvo E; LoRusso P; Wainberg Z; Cervantes A; Rodriguez-Vida A; Shemesh CS; Sane R; Mendus D; Ding H; Hendricks R; Meng R; Cho BC; Kim TW; Wu B
J Clin Pharmacol; 2024 May; 64(5):544-554. PubMed ID: 38105505
[TBL] [Abstract][Full Text] [Related]
9. Phase I dose-finding study of monotherapy with atezolizumab, an engineered immunoglobulin monoclonal antibody targeting PD-L1, in Japanese patients with advanced solid tumors.
Mizugaki H; Yamamoto N; Murakami H; Kenmotsu H; Fujiwara Y; Ishida Y; Kawakami T; Takahashi T
Invest New Drugs; 2016 Oct; 34(5):596-603. PubMed ID: 27363843
[TBL] [Abstract][Full Text] [Related]
10. IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications.
Burotto M; Zvirbule Z; Mochalova A; Runglodvatana Y; Herraez-Baranda L; Liu SN; Chan P; Shearer-Kang E; Liu X; Tosti N; Zanghi JA; Leutgeb B; Felip E
Ann Oncol; 2023 Aug; 34(8):693-702. PubMed ID: 37268157
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of dosing strategy for pembrolizumab for oncology indications.
Freshwater T; Kondic A; Ahamadi M; Li CH; de Greef R; de Alwis D; Stone JA
J Immunother Cancer; 2017; 5():43. PubMed ID: 28515943
[TBL] [Abstract][Full Text] [Related]
12. Mortality and Morbidity Effects of Long-Term Exposure to Low-Level PM
Brunekreef B; Strak M; Chen J; Andersen ZJ; Atkinson R; Bauwelinck M; Bellander T; Boutron MC; Brandt J; Carey I; Cesaroni G; Forastiere F; Fecht D; Gulliver J; Hertel O; Hoffmann B; de Hoogh K; Houthuijs D; Hvidtfeldt U; Janssen N; Jorgensen J; Katsouyanni K; Ketzel M; Klompmaker J; Hjertager Krog N; Liu S; Ljungman P; Mehta A; Nagel G; Oftedal B; Pershagen G; Peters A; Raaschou-Nielsen O; Renzi M; Rodopoulou S; Samoli E; Schwarze P; Sigsgaard T; Stafoggia M; Vienneau D; Weinmayr G; Wolf K; Hoek G
Res Rep Health Eff Inst; 2021 Sep; 2021(208):1-127. PubMed ID: 36106702
[TBL] [Abstract][Full Text] [Related]
13. Mortality-Air Pollution Associations in Low Exposure Environments (MAPLE): Phase 2.
Brauer M; Brook JR; Christidis T; Chu Y; Crouse DL; Erickson A; Hystad P; Li C; Martin RV; Meng J; Pappin AJ; Pinault LL; Tjepkema M; van Donkelaar A; Weagle C; Weichenthal S; Burnett RT
Res Rep Health Eff Inst; 2022 Jul; 2022(212):1-91. PubMed ID: 36224709
[TBL] [Abstract][Full Text] [Related]
14. Towards Fixed Dosing of Tocilizumab in ICU-Admitted COVID-19 Patients: Results of an Observational Population Pharmacokinetic and Descriptive Pharmacodynamic Study.
Moes DJAR; van Westerloo DJ; Arend SM; Swen JJ; de Vries A; Guchelaar HJ; Joosten SA; de Boer MGJ; van Gelder T; van Paassen J
Clin Pharmacokinet; 2022 Feb; 61(2):231-247. PubMed ID: 34633645
[TBL] [Abstract][Full Text] [Related]
15. Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1 TPS ≥ 50%: 3 Weekly Compared to 6 Weekly Dosing.
Jones L; Rittberg R; Leung B; Shokoohi A; Pender A; Wong S; Al-Hashami Z; Wang Y; Ho C
Curr Oncol; 2022 Nov; 29(11):8686-8692. PubMed ID: 36421338
[TBL] [Abstract][Full Text] [Related]
16. Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors.
Hurkmans DP; Sassen SDT; de Joode K; Putter L; Basak EA; Wijkhuijs AJM; Joerger M; Debets R; Koch BCP; Van der Leest CH; Schreurs MWJ; van der Veldt AAM; Aerts JGJV; Mathijssen RHJ; Koolen SLW
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34088739
[TBL] [Abstract][Full Text] [Related]
17. Extension of the Alternative Intravenous Dosing Regimens of Atezolizumab into Combination Settings through Modeling and Simulation.
Liu SN; Marchand M; Liu X; Ingle G; Maiya V; Graupner V; Elze MC; Chan P; Hsu JC; Lin A; Vadhavkar S; Wu B; Bruno R
J Clin Pharmacol; 2022 Nov; 62(11):1393-1402. PubMed ID: 35576521
[TBL] [Abstract][Full Text] [Related]
18. Real-world efficacy of atezolizumab in non-small cell lung cancer: A multicenter cohort study focused on performance status and retreatment after failure of anti-PD-1 antibody.
Furuya N; Nishino M; Wakuda K; Ikeda S; Sato T; Ushio R; Tanzawa S; Sata M; Ito K
Thorac Cancer; 2021 Mar; 12(5):613-618. PubMed ID: 33448648
[TBL] [Abstract][Full Text] [Related]
19. Real-world comparison of immune checkpoint inhibitors in non-small cell lung cancer following platinum-based chemotherapy.
Weis TM; Hough S; Reddy HG; Daignault-Newton S; Kalemkerian GP
J Oncol Pharm Pract; 2020 Apr; 26(3):564-571. PubMed ID: 31238808
[TBL] [Abstract][Full Text] [Related]
20. A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation.
Lala M; Li TR; de Alwis DP; Sinha V; Mayawala K; Yamamoto N; Siu LL; Chartash E; Aboshady H; Jain L
Eur J Cancer; 2020 May; 131():68-75. PubMed ID: 32305010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
